Growing together.

More than ever before, Merck has today what it takes to succeed worldwide tomorrow. There’s plenty of evidence of this. In the future-oriented biopharmaceuticals sector, the prospects are excellent following the integration of Serono. We want to further expand our leading position, not only in Europe. We also want to grow sustainably in all key markets and set new standards. For example in 2007, a new formulation of Rebif® – a further development of the successful multiple sclerosis therapy – was approved in the European Union, and the innovative growth hormone injection device Easypod™ was approved by the U.S. Food and Drug Administration. Global market leadership in liquid crystals for displays will also continue to generate exceptional earning power in the Chemicals business sector as flat screens continue to make their way into offices and homes. Co-developments with customers are the decisive factors here. Merck’s increased economic strength has also received objective confirmation: On June 18, 2007, our company became part of the DAX®, the blue-chip index of the 30 largest German securities, on the Frankfurt Stock Exchange.